Amgen announced Amjevita, a biosimilar to Humira, is now available in the United States. Amjevita was the first biosimilar to Humira approved by the FDA, in 2016.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMGN:
- AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
- Amgen lays off 300 employees, or 1.2% of workforce, Reuters reports
- Can Amgen (AMGN) Q4 Earnings Beat Street Expectations?
- Warren writes FTC over concerns of two pharma deals, Reuters reports
- Amgen price target cut at Piper on lower Otezla estimates
